EU safety experts begin review of leuprorelin-containing drugsEuropean safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer Share XEU safety experts begin review of leuprorelin-containing drugshttps://pharmaphorum.com/news/eu-safety-experts-begin-review-of-leuprorelin-containing-drugs/
MacroGenics looks to future with breast cancer drug margetuximabA small biotech, MacroGenics, took the market by surprise earlier this year with some surprising data from its Share XMacroGenics looks to future with breast cancer drug margetuximabhttps://pharmaphorum.com/news/macrogenics-looks-to-future-with-breast-cancer-drug-margetuximab/
Novartis steals a march in CDK4/6 market with breast cancer dataNovartis’ Kisqali has become the first drug in the CDK 4/6 inhibitor class to improve overall survival in Share XNovartis steals a march in CDK4/6 market with breast cancer datahttps://pharmaphorum.com/news/novartis-market-breast-cancer-data-asco-2019/
Novartis scores first approval for PIK3CA breast cancer drugThe FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the Share XNovartis scores first approval for PIK3CA breast cancer drughttps://pharmaphorum.com/news/novartis-scores-first-approval-for-pik3ca-breast-cancer-drug/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
AZ and Daiichi to file new breast cancer drug after trial successIn March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new Share XAZ and Daiichi to file new breast cancer drug after trial successhttps://pharmaphorum.com/news/az-and-daiichi-to-file-trastuzumab-deruxtecan/
Genetic test can predict efficacy of chemotherapy in breast cancerResearchers have found that a genetic test can successfully predict whether chemotherapy would be beneficial for patients with Share XGenetic test can predict efficacy of chemotherapy in breast cancerhttps://pharmaphorum.com/news/genetic-test-can-predict-efficacy-of-chemotherapy-in-breast-cancer/
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerThe European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced Share XAZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/
